Exelixis - Takeda's Cabometyx Scores Approval In Japan For Kidney Cancer

  • Exelixis Inc's EXEL collaborating partner Takeda Pharmaceutical Co Ltd TAK and Ono Pharmaceutical Co Ltd have received approval for Cabometyx (cabozantinib) in Japan.
  • The approval covers Cabometyx combined with Bristol-Myers Squibb Co's BMY Opdivi (nivolumab) for unresectable or metastatic renal cell carcinoma (RCC).
  • The approval is based on the CheckMate 9ER Phase 3 trial. 
  • The Cabometyx combination demonstrated superior overall survival and doubled median progression-free survival and objective response rate versus sunitinib, with a favorable safety profile.
  • Per the terms of Exelixis and Takeda's collaboration and license agreement, Exelixis will receive a milestone payment of $20 million from Takeda. 
  • Related content: Benzinga's Full FDA Calendar.
  • Price Action: TAK stock is down 0.30% at $16.77 during the premarket session on the last check Thursday, and EXEL stock closed 0.11% lower at $18.91 on Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareFDAGeneralBriefsrenal cell carcinoma
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!